Osteodifferentiated Mesenchymal Stem Cells from Bone Marrow and Adipose Tissue Express HLA-G and Display Immunomodulatory Properties in HLA-Mismatched Settings: Implications in Bone Repair Therapy

Table 1

MSC from BM after osteodifferentiation and licensing by IFN-γ and TNF-α do not induce PBMC proliferation in allogenic conditions.

R : S^a; ratio	MSC-BM	MSC-BM; IFN-γ/TNF-α	Os-MSC-BM	Os-MSC-BM; IFN-γ/TNF-α
1 : 0.5	4.3±2.1^b	1.1±0.3	3.3±0.3	1.7±0.2
1 : 0.25	4.5±1.4	1.0±0.3	3.1±0.1	1.8±0.5
1 : 0.12	5.3±1.9	1.1±0.4	3.2±1.0	2.3±1.2
1 : 0.06	5.4±2.4	1.4±0.5	2.6±1.1	3.9±3.1
1 : 0.03	4.3±1.7	1.4±0.5	2.2±0.2	2.1±1.2

aPBMC from healthy individuals were used as responder cells towards BM-derived MSCs pretreated with IFN-γ and TNF-α (MSC-BM IFN-γ/TNF-α) or not (MSC-BM) as stimulating cells at various responder : stimulator (R : S) ratios. Similar experiments were performed with BM-derived MSCs committed to osteodifferentiation process and pretreated with IFN-γ and TNF-α (Os-MSC-BM IFN-γ/TNF-α) or not (Os-MSC-BM) as stimulating cells.
^bData are mean ± s.e.m. of alloproliferation percentage obtained with 5 and 3 distinct healthy donors for MSC-BM and Os-MSC-BM experiments, respectively. This percentage is calculated considering PBMC stimulated with LCL* as 100% alloproliferation.